Position Papers
-
Global Call to Action for Thalassaemia
This important document, prepared by TIF in close collaboration with the Government of Cyprus, serves as a comprehensive and evidence-based guide to strengthening national responses…
Read More » -
The Views of TIF on Advanced Therapy Medicinal Products (ATMPs)
This Position Paper discusses the significant barriers that affect patient access to Advanced Therapy Medicinal Products (ATMPs) and calls for policymakers, healthcare professionals, and society at large to acknowledge and…
Read More » -
Strengthening the Resilience of EU Health Systems
This position paper examines the growing pressures that emerging public health challenges place on national health systems, focusing on the rising prevalence of thalassaemia and its potential implications for the…
Read More » -
Social Health Protection for People with Thalassaemia
To support the social health protection of people with thalassaemia and other haemoglobin disorders, TIF developed a Disability Risk Assessment Chart to guide individualised assessments. Its parameters are selected based…
Read More » -
EU Regulation for Blood, Tissues and Cells
The Thalassaemia International Federation (TIF) welcomes the European Commission’s proposed Regulation on Blood, Tissues and Cells as a significant step towards strengthening safety for blood donors and recipients across the…
Read More » -
Demanding Access to Existing and Upcoming Gene Therapies for Beta Thalassaemia
The Thalassaemia International Federation (TIF) expresses its deep disappointment at bluebird bio’s decision to wind down its European operations and make Zynteglo™, its gene therapy for beta-thalassaemia, available exclusively in…
Read More » -
Addressing Blood Supply Issues Linked to COVID-19 Vaccination Deferral Times
In this position statement, TIF addresses common questions and concerns among blood donors about COVID-19 vaccination and blood donation.
Read More » -
Accessibility of Gene Therapy for Thalassaemia
Gene therapy represents a long-awaited breakthrough for people with thalassaemia. National health authorities must recognise the value of innovative treatments, considering both the disease’s impact on patients and families and…
Read More » -
EU Policy Recommendations for Thalassaemia and Sickle Cell Disease
Developed under TIF’s “Thalassaemia in Action” (THALIA) programme (2018–2021), this document examines the challenges facing people with thalassaemia and sickle cell disease in the EU. It sets out recommendations for…
Read More » -
COVID-19 Vaccines and Haemoglobin Disorders
In view of the plans made by national health authorities in every country across the world for the widespread vaccination of individuals against the SARS-CoV-2 virus, TIF herein presents the Federation’s…
Read More »